Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia. The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients. It also developing  Niktimvo, a colony stimulating factor-1 receptor, blocking antibody, which is in phase 2 clinical trial for the treatment of chronic graft-versus-host disease. The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Period	Debt/Equity
2016-12-31	0.30
2017-12-31	0.32
2018-12-31	0.58
2019-12-31	1.01
2020-12-31	0.19
2021-12-31	0.10
2022-12-31	0.06
2023-12-31	0.11
2024-12-31	1.52

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNDX	$24.57	-0.28%	0.75M
3
4
5

Syndax Pharmaceuticals Inc. (SNDX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Syndax Pharmaceuticals Inc. Data in Excel

More SNDX Financial Data